News

A Phase 2/3 multicenter study of Osivelotor has been approved to proceed by India’s Central Drugs Standard Control Organisation (CDSCO). Aimed at treating Sickle Cell Disease, the drug (GBT021601) has …

A clinical trial led by Dr. Ali Taher at the American University of Beirut Medical Center, shows that Mitapivat has potential benefits for non-transfusion dependent thalassemia patients. Developed by Agios …

Tim Randolph has been recognized by the National Academy of Inventors for his innovative work in developing more accessible diagnostics for sickle cell disease. The research has led to the …

We are happy to see Functional Fluidics expanding to Africa and setting up a new research clinic and laboratory in Nigeria. And we are truly grateful for the significant contributions …

The Department of Health of Puerto Rico has granted authorization to market Endari, an oral powder treatment for sickle cell disease (SCD). The first FDA-backed oral glutamine, Endari has been …

Sickle cell disease affects a significant number of individuals in North Carolina, particularly within the Black community, where about 95 percent of cases are found. This genetic blood disorder not …

A recent study conducted in Uganda revealed that treatment with hydroxyurea significantly reduced the incidence of severe or invasive infections among children with sickle cell anemia by 60%. Sickle cell …

The first patient has been administered with BEAM-101 in the BEACON trial, a Phase 1/2 clinical study conducted by Beam Therapeutics for sickle cell disease (SCD). Following the transplantation, stem …

Emmaus Life Sciences has launched Endari, a medication aimed at alleviating acute complications in individuals battling sickle cell disease, now accessible via prescription across the United States. Sickle cell disease, …